
Appendix C. Genomic Medicine Assistant Demo Multi-Gene Panel Laboratory Reports

Figure C.1 Pharmacogenomic Sequencing Panel Report - Results Page (CYP2C19)



Genomic Medicine Assistant, 2016©

While the investigators in the study have made every effort to ensure that the information presented is consistent with current practices, all information presented was prepared for simulated conditions and may not reflect all aspects of standard medical care.

Figure C.2 Pharmacogenomic Sequencing Panel Report - Test Information Page (*CYP2C19*)

Genomic Medicine Assistant **Pharmacogenomic Sequencing Panel Report** Results Test Information Mouse, Mickey Whole Blood Patient Specimen Type: Patient DOB 06/15/1945 Collection Date: 04/22/2015 04/22/2015 Ordering Provider Dr. Seuss Received Date: Disney Medical Center 600254 Lab Accession No Institution:

Test Methods and Limitations

Pharmacogenomic Sequencing Panel

A sequencing panel of 84 genes known to be involved in drug metabolism was performed using the MiSeqDxTMA technology (Illumina, San Diego, CA). The panel was designed to identify DNA sequence variants relevant to drug therapy decisions and to cover all coding regions plus at least 10 bp upstream and downstream. Only pathogenic or likely pathogenic variants are reported; variants of unknown significance are not returned.

Genes to be sequenced include GN01, GN02, GN03, GN04, GN05, GN06, GN07, GN08, GN09, GN10, GN11, GN12, GN13, GN14, GN15, GN16, GN17, GN18, GN19, GN20, GN21, GN22, GN23, GN24, GN25, GN26, GN27, GN28, GN29, GN30, GN31, GN32, GN33, GN34, GN35, GN36, GN37, GN38, GN39, GN40, GN41, GN42, GN43, GN44, GN45, GN46, GN47, GN48, GN49, GN50, GN51, GN52, GN53, GN54, GN55, GN56, GN57, GN58, GN59, GN60, GN61, GN62, GN63, GN64, GN65, GN66, GN67, GN68, GN69, GN70, GN71, GN72, GN73, GN74, GN75, GN76, GN77, GN78, GN79, GN80, GN81, GN82, GN83, and GN84 that are known to be associated with drug metabolism.

Limitations

This assay will not detect large deletions or duplications, variants in genes or regions not included on the panel or in areas of inadequate coverage, or low-level mosaicism, Only variants classified according to the ACMG criteria as pathogenic and likely pathogenic will be reported. Sequencing technology is continually evolving, and the interpretation of genetic findings may change over time.

DISCLAIMER

This test was developed and its performance characteristics determined by the University of Schrek Genomics Laboratory. It has not been cleared or approved by the FDA. This laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) as qualified to perform high complexity clinical laboratory testing. This test is for clinical purposes. It should not be regarded as investigational or for research.

Testing Performed at:

University of Schrek Genomics Laboratory 12345 Fantasy Road Orlando, FL 56789 123-234-3456

Return to inbox

Genomic Medicine Assistant, 2016©

While the investigators in the study have made every effort to ensure that the information presented is consistent with current practices, all information presented was prepared for simulated conditions and may not reflect all aspects of standard medical care.